The blood screening market is experiencing significant growth as healthcare systems worldwide prioritize safe blood transfusion practices and early detection of infectious diseases. Blood screening involves testing donated blood for pathogens such as HIV, hepatitis B, hepatitis C, and other transfusion-transmissible infections to ensure the safety of blood supplies.
The increasing demand for blood donations, rising awareness about blood safety, and advancements in diagnostic technologies are key factors contributing to the expansion of this market. Blood screening plays a critical role in preventing the transmission of infectious diseases and improving patient outcomes in surgeries, trauma care, and chronic disease management.
Technological advancements such as nucleic acid testing and automated screening systems are enhancing the accuracy and efficiency of blood screening processes. These innovations are enabling faster detection of infections, reducing the risk of contaminated blood entering the supply chain.
The global blood screening market size was valued at USD 3.18 billion in 2024.
It is expected to grow from USD 3.55 billion in 2025 to USD 8.61 billion by 2033, registering a CAGR of 11.7% during the forecast period (2025-2033).
Get Full Report Now: https://straitsresearch.com/report/blood-screening-market
One of the primary drivers of the blood screening market is the increasing prevalence of infectious diseases. The growing incidence of conditions such as HIV, hepatitis, and other blood-borne infections has led to a greater emphasis on safe blood transfusion practices.
The rising number of surgical procedures and trauma cases is also contributing to market growth. Hospitals and healthcare facilities require a steady supply of safe blood, which increases the demand for reliable screening technologies.
Advancements in screening technologies, including nucleic acid testing and enzyme-linked immunosorbent assay, are enhancing detection capabilities and improving efficiency. These technologies enable early detection of infections, reducing the risk of transmission.
Government initiatives and regulations aimed at ensuring blood safety are further supporting market expansion. Regulatory bodies are implementing stringent guidelines for blood screening, encouraging the adoption of advanced testing methods.
Get Your Sample Report Here: https://straitsresearch.com/report/blood-screening-market/request-sample
Despite its growth potential, the blood screening market faces several challenges. High costs associated with advanced screening technologies can limit adoption, particularly in developing regions.
Limited access to healthcare infrastructure and diagnostic facilities in certain areas may also hinder market growth.
The complexity of testing procedures and the need for skilled professionals can pose operational challenges for healthcare providers.
Additionally, the risk of false positives and false negatives in certain testing methods may affect the reliability of screening results.
The blood screening market is segmented into nucleic acid testing, enzyme-linked immunosorbent assay, rapid tests, and others.
Nucleic acid testing dominates the market due to its high sensitivity and ability to detect infections at an early stage. This technology is widely used for screening blood donations for viral infections.
Enzyme-linked immunosorbent assay is commonly used for detecting antibodies and antigens in blood samples. It is a cost-effective and widely adopted method.
Rapid tests are gaining popularity due to their quick results and ease of use, particularly in emergency and point-of-care settings.
The market is segmented into reagents and kits, instruments, and software and services.
Reagents and kits hold a significant share due to their recurring demand in blood screening procedures.
Instruments include automated analyzers and screening systems used in laboratories and blood banks.
Software and services support data management, analysis, and system maintenance.
The blood screening market is segmented into hospitals, blood banks, diagnostic laboratories, and others.
Blood banks dominate the market as they are responsible for collecting, testing, and storing blood for transfusions.
Hospitals are major users of screened blood for surgeries and medical treatments.
Diagnostic laboratories perform screening tests and support healthcare facilities with accurate results.
North America holds a significant share of the blood screening market due to advanced healthcare infrastructure, high awareness of blood safety, and strong regulatory frameworks.
Europe is witnessing steady growth, supported by government initiatives and increasing adoption of advanced screening technologies.
Asia-Pacific is expected to experience the fastest growth due to rising healthcare investments, increasing prevalence of infectious diseases, and growing awareness of blood safety.
Other regions are gradually improving their blood screening capabilities as healthcare systems develop.
Abbott Laboratories – Abbott is a leading provider of diagnostic solutions, including advanced blood screening technologies and systems.
F. Hoffmann-La Roche Ltd. – Roche offers a wide range of diagnostic products, including blood screening assays and instruments.
Bio-Rad Laboratories, Inc. – Bio-Rad specializes in diagnostic and research products, including blood screening solutions.
Grifols, S.A. – Grifols is a global healthcare company focused on plasma-derived medicines and diagnostic systems.
Siemens Healthineers AG – Siemens Healthineers provides innovative diagnostic technologies, including blood screening systems.
Ortho Clinical Diagnostics – Ortho offers diagnostic solutions for blood screening and transfusion medicine.
Thermo Fisher Scientific Inc. – Thermo Fisher provides a comprehensive range of laboratory products and diagnostic solutions.
The blood screening market is poised for substantial growth, driven by increasing demand for safe blood transfusions, rising prevalence of infectious diseases, and advancements in diagnostic technologies. The adoption of nucleic acid testing and automated screening systems is enhancing the accuracy and efficiency of blood screening processes.
While challenges such as high costs and infrastructure limitations exist, ongoing technological advancements and government initiatives are expected to support market growth. As healthcare systems continue to prioritize patient safety and disease prevention, blood screening will remain a critical component of modern medical practices.
Blood screening is the process of testing blood for infectious diseases and other contaminants to ensure its safety for transfusion.
The market is driven by increasing prevalence of infectious diseases, rising demand for safe blood, and advancements in screening technologies.
High costs, limited infrastructure, and testing complexities are major challenges.
Nucleic acid testing dominates due to its high sensitivity and early detection capabilities.
Asia-Pacific is the fastest-growing region due to increasing healthcare investments and awareness.
Straits Research is a leading research and intelligence organisation, specialising in research, analytics, and advisory services, along with providing business insights & research reports.
Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)